Clinical trials
Recruiting Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
437 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 18 |
| 2021 | 18 |
| 2022 | 27 |
| 2023 | 39 |
| 2024 | 60 |
| 2025 | 141 |
| 2026 | 97 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 437 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 6 |
| Peking Union Medical College Hospital | 5 |
| Peking University First Hospital | 5 |
| Institut National de la Santé Et de la Recherche Médicale, France | 4 |
| Skane University Hospital | 4 |
| The First Affiliated Hospital of Xiamen University | 4 |
| University Hospital, Lille | 4 |
| Anhui Provincial Hospital | 3 |
| Changhai Hospital | 3 |
| China-Japan Friendship Hospital | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease | 437 |
| Lung Neoplasms | 42 |
| Prostatic Neoplasms | 37 |
| Neoplasms | 28 |
| Asthma | 27 |
| Colorectal Neoplasms | 14 |
| Stomach Neoplasms | 13 |
| Pulmonary Disease, Chronic Obstructive | 12 |
| Pulmonary Embolism | 12 |
| Pancreatic Neoplasms | 11 |
Trials
Showing 76 to 100 of 437. Each trial links to its page on Pharma Observatory.
337 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.